Astellas Pharma Inc. (TYO:4503)
1,385.00
-5.50 (-0.40%)
Jun 25, 2025, 9:44 AM JST
Astellas Pharma Revenue
In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T JPY with 19.25% growth. Astellas Pharma had revenue of 459.29B in the quarter ending March 31, 2025, with 10.78% growth.
Revenue
1,912.32B
Revenue Growth
+19.25%
P/S Ratio
1.30
Revenue / Employee
140.17M
Employees
13,643
Market Cap
2,489.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,912.32B | 308.65B | 19.25% |
Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Takeda Pharmaceutical Company | 4,581.55B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 866.03B |
Terumo | 1,036.17B |
Otsuka Holdings | 2,393.18B |
Shionogi & | 438.30B |
Olympus | 997.33B |
Astellas Pharma News
- 11 days ago - Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan - PRNewsWire
- 11 days ago - Lupin shares in focus after US Court rejects plea in Astellas Patent case - Business Upturn
- 26 days ago - Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PRNewsWire
- 27 days ago - Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers - PRNewsWire
- 4 weeks ago - Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Benzinga
- 4 weeks ago - Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio - PRNewsWire
- 7 weeks ago - Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses - PRNewsWire
- 2 months ago - Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript - Seeking Alpha